Literature DB >> 16533614

Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs.

Giuseppe Rossoni1, Barbara Manfredi, Roberta Razzetti, Maurizio Civelli, Ferruccio Berti.   

Abstract

This study evaluated the bronchodilating activity of the beta(2)-agonist carmoterol and the muscarinic M(3)-antagonist tiotropium, given intratracheally alone or in combination in anaesthetized artificially ventilated normal and actively sensitized guinea-pigs. Carmoterol (0.3-100pmol) and tiotropium (10-1000pmol) were superfused (0.01ml/min) for 5min before challenges with acetylcholine (20mug/kg i.v.), histamine (10mug/kg i.v.) or ovalbumin (5mg/kg i.v.). Both compounds given alone were markedly active against all the challenges. Tiotropium resulted more effective towards cholinergic challenge and carmoterol was very potent against histamine and ovalbumin-induced reaction, being effective already at 1pmol. In the presence of tiotropium, the bronchodilating activity of carmoterol was significantly augmented. The ED(50) value of carmoterol on the acetylcholine challenge was reduced by about 10 and 28 times (0.1 and 0.3pmol of tiotropium), that on the histamine one by 4.5 and 13 times (1 and 3pmol of tiotropium) and that on the ovalbumin-induced one by 8 and 25 times (10 and 30pmol of tiotropium). A positive interaction was also evident when other parameters were evaluated. The histamine-induced release of thromboxane B(2) was markedly reduced (56%, P<0.001) by combining completely ineffective doses of the two drugs (0.3 and 3pmol for carmoterol and tiotropium, respectively). In ovalbumin-challenged animals the time to death, amounting in control animals to 7.2+/-0.9min, was dose-dependently prolonged up to achieve complete protection from death with combination of 1 and 30pmol of carmoterol and tiotropium, respectively. The favorable interaction between carmoterol and tiotropium can represent a good option in the control of bronchopulmonary diseases marked by an increase of airway resistances.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533614     DOI: 10.1016/j.pupt.2006.01.004

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  10 in total

1.  Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility.

Authors:  R Venkatasamy; D Spina
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

Review 2.  ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?

Authors:  Maria Gabriella Matera; Mario Cazzola
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Hydrogen sulfide attenuates neurodegeneration and neurovascular dysfunction induced by intracerebral-administered homocysteine in mice.

Authors:  P K Kamat; A Kalani; S Givvimani; P B Sathnur; S C Tyagi; N Tyagi
Journal:  Neuroscience       Date:  2013-07-31       Impact factor: 3.590

Review 4.  Novel long-acting bronchodilators for COPD and asthma.

Authors:  M Cazzola; M G Matera
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

Review 5.  Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions.

Authors:  Adeeb Bulkhi; Farnaz Tabatabaian; Thomas B Casale
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

6.  Neuroprotective Effect of Hydrogen Sulfide in Hyperhomocysteinemia Is Mediated Through Antioxidant Action Involving Nrf2.

Authors:  Mohit Kumar; Rajat Sandhir
Journal:  Neuromolecular Med       Date:  2018-08-13       Impact factor: 3.843

Review 7.  The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease.

Authors:  Philippa R Dale; Hana Cernecka; Martina Schmidt; Mark R Dowling; Steven J Charlton; Michael P Pieper; Martin C Michel
Journal:  Curr Opin Pharmacol       Date:  2014-03-27       Impact factor: 5.547

8.  Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?

Authors:  David Price; Leonard Fromer; Alan Kaplan; Thys van der Molen; Miguel Román-Rodríguez
Journal:  NPJ Prim Care Respir Med       Date:  2014-07-17       Impact factor: 2.871

Review 9.  COPD: the patient perspective.

Authors:  Paul W Jones; Henrik Watz; Emiel F M Wouters; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-02-19

Review 10.  Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?

Authors:  Domenico Spina
Journal:  Eur Clin Respir J       Date:  2015-03-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.